Overview

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Status:
Completed

Trial end date:
2017-05-01

Target enrollment:

Participant gender:

Summary

This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer to evaluate tumor response in the breast and the axilla.

Phase:

Phase 2

Details

Lead Sponsor:

AZ-VUB

Collaborators:

Universitair Ziekenhuis Brussel
Universitaire Ziekenhuizen Leuven

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Epirubicin
Paclitaxel